Literature DB >> 28082444

Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.

Eric J Duncavage1, Geoffrey L Uy2, Allegra A Petti3, Christopher A Miller2,3, Yi-Shan Lee1, Bevan Tandon1, Feng Gao4, Catrina C Fronick3, Michelle O'Laughlin3, Robert S Fulton3, Richard K Wilson3, Meagan A Jacoby2, Amanda F Cashen2, Lukas D Wartman2, Matthew J Walter2, Peter Westervelt2, Daniel C Link2, John F DiPersio2, Timothy J Ley2,3, John S Welch2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28082444      PMCID： PMC5345736          DOI： 10.1182/blood-2016-10-745273

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  24 in total

1.  Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications.

Authors:  Felicitas Thol; Robin Bollin; Marten Gehlhaar; Carolin Walter; Martin Dugas; Karl Josef Suchanek; Aylin Kirchner; Liu Huang; Anuhar Chaturvedi; Martin Wichmann; Lutz Wiehlmann; Rabia Shahswar; Frederik Damm; Gudrun Göhring; Brigitte Schlegelberger; Richard Schlenk; Konstanze Döhner; Hartmut Döhner; Jürgen Krauter; Arnold Ganser; Michael Heuser
Journal:  Blood       Date:  2013-12-13       Impact factor: 22.113

2.  High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS).

Authors:  A M Mohamedali; J Gäken; M Ahmed; F Malik; A E Smith; S Best; S Mian; T Gaymes; R Ireland; A G Kulasekararaj; G J Mufti
Journal:  Leukemia       Date:  2015-05-06       Impact factor: 11.528

3.  Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts.

Authors:  Patricia Font; Javier Loscertales; Carlos Soto; Pilar Ricard; Carolina Muñoz- Novas; Estela Martín-Clavero; Montserrat López-Rubio; Luis Garcia-Alonso; Marta Callejas; Alfredo Bermejo; Celina Benavente; Mónica Ballesteros; Teresa Cedena; María Calbacho; Raquel Urbina; Jesús Villarrubia; Santiago Gil; José María Bellón; José Luis Diez-Martin; Ana Villegas
Journal:  Ann Hematol       Date:  2014-11-13       Impact factor: 3.673

4.  Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes.

Authors:  Leonor Senent; Leonor Arenillas; Elisa Luño; Juan C Ruiz; Guillermo Sanz; Lourdes Florensa
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

5.  Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses.

Authors:  Michael R Loken; Sung-Chao Chu; Wayne Fritschle; Michael Kalnoski; Denise A Wells
Journal:  Cytometry B Clin Cytom       Date:  2008-06-11       Impact factor: 3.058

6.  Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia.

Authors:  Jeffery M Klco; Christopher A Miller; Malachi Griffith; Allegra Petti; David H Spencer; Shamika Ketkar-Kulkarni; Lukas D Wartman; Matthew Christopher; Tamara L Lamprecht; Nicole M Helton; Eric J Duncavage; Jacqueline E Payton; Jack Baty; Sharon E Heath; Obi L Griffith; Dong Shen; Jasreet Hundal; Gue Su Chang; Robert Fulton; Michelle O'Laughlin; Catrina Fronick; Vincent Magrini; Ryan T Demeter; David E Larson; Shashikant Kulkarni; Bradley A Ozenberger; John S Welch; Matthew J Walter; Timothy A Graubert; Peter Westervelt; Jerald P Radich; Daniel C Link; Elaine R Mardis; John F DiPersio; Richard K Wilson; Timothy J Ley
Journal:  JAMA       Date:  2015-08-25       Impact factor: 56.272

7.  Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification.

Authors:  P Font; J Loscertales; C Benavente; A Bermejo; M Callejas; L Garcia-Alonso; A Garcia-Marcilla; S Gil; M Lopez-Rubio; E Martin; C Muñoz; P Ricard; C Soto; P Balsalobre; A Villegas
Journal:  Ann Hematol       Date:  2012-09-05       Impact factor: 3.673

8.  Assessment of Minimal Residual Disease in Standard-Risk AML.

Authors:  Adam Ivey; Robert K Hills; Michael A Simpson; Jelena V Jovanovic; Amanda Gilkes; Angela Grech; Yashma Patel; Neesa Bhudia; Hassan Farah; Joanne Mason; Kerry Wall; Susanna Akiki; Michael Griffiths; Ellen Solomon; Frank McCaughan; David C Linch; Rosemary E Gale; Paresh Vyas; Sylvie D Freeman; Nigel Russell; Alan K Burnett; David Grimwade
Journal:  N Engl J Med       Date:  2016-01-20       Impact factor: 91.245

9.  Evaluation of bone marrow aspirates in patients with acute myeloid leukemia at day 14 of induction therapy.

Authors:  João Tadeu D Souto Filho; Monique M Loureiro; Wolmar Pulcheri; José Carlos Morais; Marcio Nucci; Rodrigo D Portugal
Journal:  Diagn Pathol       Date:  2015-07-25       Impact factor: 2.644

10.  Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Luca Malcovati; Sudhir Tauro; Gunes Gundem; Peter Van Loo; Chris J Yoon; Peter Ellis; David C Wedge; Andrea Pellagatti; Adam Shlien; Michael John Groves; Simon A Forbes; Keiran Raine; Jon Hinton; Laura J Mudie; Stuart McLaren; Claire Hardy; Calli Latimer; Matteo G Della Porta; Sarah O'Meara; Ilaria Ambaglio; Anna Galli; Adam P Butler; Gunilla Walldin; Jon W Teague; Lynn Quek; Alex Sternberg; Carlo Gambacorti-Passerini; Nicholas C P Cross; Anthony R Green; Jacqueline Boultwood; Paresh Vyas; Eva Hellstrom-Lindberg; David Bowen; Mario Cazzola; Michael R Stratton; Peter J Campbell
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113
View more
  13 in total

Review 1.  When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter.

Authors:  Gregory W Roloff; Elizabeth A Griffiths
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  Treatments targeting MDS genetics: a fool's errand?

Authors:  Amy E DeZern
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 3.  When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter.

Authors:  Gregory W Roloff; Elizabeth A Griffiths
Journal:  Blood Adv       Date:  2018-11-13

4.  Acute myeloid leukemia-induced T-cell suppression can be reversed by inhibition of the MAPK pathway.

Authors:  Kaycee B Moshofsky; Hyun J Cho; Guanming Wu; Kyle A Romine; Matthew T Newman; Yoko Kosaka; Shannon K McWeeney; Evan F Lind
Journal:  Blood Adv       Date:  2019-10-22

5.  MRD evaluation of AML in clinical practice: are we there yet?

Authors:  Sylvie D Freeman; Christopher S Hourigan
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

6.  Somatic mutations and clonal hematopoiesis in congenital neutropenia.

Authors:  Jun Xia; Christopher A Miller; Jack Baty; Amrita Ramesh; Matthew R M Jotte; Robert S Fulton; Tiphanie P Vogel; Megan A Cooper; Kelly J Walkovich; Vahagn Makaryan; Audrey A Bolyard; Mary C Dinauer; David B Wilson; Adrianna Vlachos; Kasiani C Myers; Robert J Rothbaum; Alison A Bertuch; David C Dale; Akiko Shimamura; Laurence A Boxer; Daniel C Link
Journal:  Blood       Date:  2017-11-01       Impact factor: 22.113

7.  Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma.

Authors:  Jianhua Liu; Yahui Liu; Lingyu Meng; Kai Liu; Bai Ji
Journal:  Oncol Rep       Date:  2017-06-14       Impact factor: 3.906

8.  Depletion of ZBTB38 potentiates the effects of DNA demethylating agents in cancer cells via CDKN1C mRNA up-regulation.

Authors:  Claire Marchal; Maud de Dieuleveult; Claude Saint-Ruf; Nadège Guinot; Laure Ferry; Sara T Olalla Saad; Mariana Lazarini; Pierre-Antoine Defossez; Benoit Miotto
Journal:  Oncogenesis       Date:  2018-10-11       Impact factor: 7.485

Review 9.  Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia.

Authors:  Jennifer M Yoest; Cara Lunn Shirai; Eric J Duncavage
Journal:  Front Cell Dev Biol       Date:  2020-05-08

10.  Clinical implications of subclonal TP53 mutations in acute myeloid leukemia.

Authors:  Katharina T Prochazka; Gudrun Pregartner; Frank G Rücker; Ellen Heitzer; Gabriel Pabst; Albert Wölfler; Armin Zebisch; Andrea Berghold; Konstanze Döhner; Heinz Sill
Journal:  Haematologica       Date:  2018-10-11       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.